3 Underrated Vanguard ETFs with 15%+ Upside Potential
Vanguard ETFs are often known for their low costs and long-term stability, but not all of them get the attention they deserve. Some lesser-known Va...
Moderna Inc. (MRNA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Laurion Capital Management Benjamin A. Smith | 36,063 | $6,944,652 | 0.11% | |
| 2. | Motley Fool Asset Management Bryan Hinmon | 30,047 | $5,786,151 | +348% | 0.22% |
| 3. | Sivik Global Healthcare Krishen Sud | 10,000 | $1,925,700 | 1.1% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.53 | 57,493 | $1,812,754.29 | 9,210,686 | 2025-03-03 | Filing | |
| $31.04 | 102,821 | $3,191,563.84 | 9,153,193 | 2025-03-03 | Filing | |
| $31.76 | 31,620 | $1,004,251.20 | 312,027 | 2025-03-03 | Filing | |
| $19.00 | 52,631 | $999,989.00 | 420,407 | 2020-02-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $220.72 | 39,145 | $8,640,084.40 | 1,636,565 | 2026-10-15 | Filing | |
| $214.15 | 450 | $96,367.50 | 1,599,258 | 2026-10-14 | Filing | |
| $213.47 | 38,774 | $8,277,085.78 | 1,599,708 | 2026-10-14 | Filing | |
| $146.07 | 40,281 | $5,883,845.67 | 1,562,029 | 2026-09-15 | Filing | |
| $144.13 | 40,294 | $5,807,574.22 | 1,525,858 | 2026-09-14 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,151,259 | $414,267,946 | 2.85% | |
| 2. | 1,160,945 | $223,563,179 | 3% | |
| 3. | 1,000,056 | $192,580,784 | 18.17% | |
| 4. | 749,208 | $144,274,985 | 2.51% | |
| 5. | 152,218 | $29,312,620 | 1.2% |
News See All
Moderna Stock (MRNA) Falls 3% as Analysts Question $80 Billion Valuation Despite CEO’s Defense of Cancer Vaccine
Moderna ($MRNA) shares fell 3% in pre-market trading today after Wall Street analysts warned that its Phase 3 melanoma trial results were weaker th...
Moderna stock keeps falling in premarket trading today. What’s worrying investors and what Wall Street sees next?
The selling isn’t over for Moderna (NASDAQ:MRNA), with shares of the vaccine maker tumbling another 9% in Monday’s premarket trading after losing a...
Moderna’s Cancer Vaccine Earns Praise from Doctors amid Stock Selloff
Biotech company Moderna ($MRNA) saw its shares fall by as much as 25% on Thursday, October 22, despite positive results from a late-stage trial of ...
Why Is Moderna Stock (MRNA) Still Falling After Thursday’s 18% Plunge?
Shares of U.S. vaccine maker Moderna ($MRNA) fell another 6% to about $191 during Friday’s pre-market session, extending Thursday’s 17.57% plunge. ...
Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Offers Upside, According to Wall Street?
Moderna ($MRNA) and BioNTech ($BNTX) are biotech stocks focused on cancer vaccines as they enter their next growth phase. According to TipRanks Com...
Moderna Stock Is Crashing Over 20%: What Spooked Investors and What Wall Street Sees Next
Moderna (NASDAQ:MRNA) shares are taking a beating Thursday, plunging about 23% following reports that highly anticipated clinical trial data for it...
Moderna Stock (MRNA) Plunges 25% as Data Is Leaked Online
Expectations are high for the company’s new cancer drug.
Moderna Stock Jumps 4.5% as Major Cancer Vaccine Catalyst Approaches
Shares of vaccine maker Moderna ($MRNA) rose by about 4.5% in Thursday trading as investors looked ahead to an October 24 presentation of detailed ...
3 Overlooked Vanguard ETFs with 19%+ Upside
Vanguard ETFs are often known for their low costs and long-term stability, but not all of them get the attention they deserve. Some lesser-known Va...
Hedge Fund Resource Center